مقالات پذیرفته شده در نهمین کنگره بین المللی زیست پزشکی
Synergistic Effects of Cold Atmospheric Plasma and Nanomedicine in Reactive Oxygen Species-Based Cancer Therapy
Synergistic Effects of Cold Atmospheric Plasma and Nanomedicine in Reactive Oxygen Species-Based Cancer Therapy
Faezeh Roshanbakht,1,*Ali Saatchifard,2Neda Attaran Kakhki,3
1. Department of Biomedical Engineering, Faculty of Medical Sciences and Technologies, Science and Research Branch, Islamic Azad University, Tehran, Iran 2. Biomaterials Group, Department of Nanotechnology and Advanced Materials, Materials and Energy Research Center (MERC), Karaj, Iran 3. Department of Medical Nanotechnology, Islamic Azad University, Tehran, Iran
Introduction: Cancer remains one of the leading causes of global mortality, and current therapies are limited by drug resistance, toxicity, and heterogeneous patient responses. Cold Atmospheric Plasma (CAP) generates reactive oxygen and nitrogen species (ROS/RNS) with selective anticancer effects, yet issues such as limited tissue penetration and dose control restrict its clinical application. Nanomedicine, through smart carriers such as metallic nanoparticles, liposomes, and polymers, offers a promising strategy to overcome these barriers and enhance the therapeutic potential of CAP.
Methods: This review was conducted through a narrative search in PubMed, Scopus, and Web of Science up to February 2025. The keywords “Cold Atmospheric Plasma,” “Nanomedicine,” “Reactive Oxygen Species,” and “Cancer Therapy” were used. After screening 272 records, 34 eligible articles including in vitro, in vivo, and early clinical studies were included and critically analyzed.
Results: Most studies (≈65%) were in vitro, demonstrating that CAP combined with nanomaterials enhances ROS generation, promotes apoptosis and ferroptosis, and suppresses tumor growth. About 20% were in vivo studies, confirming tumor volume reduction and survival benefits in animal models. Early-phase clinical reports in skin and pancreatic cancers indicated tumor shrinkage and improved patient quality of life. Overall, evidence highlights the synergistic effects of CAP and nanomedicine in improving selectivity, efficacy, and immune responses, though concerns about long-term safety, penetration depth, and lack of standard protocols remain.
Conclusion: The integration of Cold Atmospheric Plasma with nanomedicine represents a transformative approach to cancer therapy by increasing therapeutic efficacy while reducing systemic toxicity. Further preclinical validation, standardized protocols, and well-designed clinical trials are required before routine clinical translation.